Transcript of "Presentation mvcc 2010_ver_april_17"
Monterrey Venture Capital Conference BPS-Cardiac Medical Device by knavii.
Did you Know?• “Hearth blood pressure is highly related to Cardiac diseases and cause 7 million deaths worldwide” – WHO report.• “Worldwide 418,000 persons die every year because of hearth strokes” – WHO report.
BPS-Cardiac: The Pain• People who needs CVBP (Central Venous Blood Pressure Measurement).Heart attack Intensive Care Units (ICU) Catheterization: Expensive & Risky, Procedure Potential Problems: Infections, Blood shifts.
BPS-Cardiac: Value Proposition• A painless, low cost, technology to measure CVBP. Stake Holder Value Created Patient and his Family Lessen Pain and suffering Physician & Nurse Less en Lawsuits for wrong catheterizations. Payers (Public & Private) Reduce the current Cost of the procedure Hospitals Increase the productivity (facilities) Government Regulator Secure and effective treatments (Law/Reg.)
BPS-Cardiac: Technology• A disruptive non-invasive technology that measure CVBP (Lab scale prototype is ready!!!!)
BPS-Cardiac: Market Opportunity Global Cardiac-Catheterization Market Potential Market: US Market (ICU Beds) (BUSD)115 CAGR 12.3% 12.2 Hospitals212 11.1 2,754 10.0 8.9 BPS- 9 7.7 Beds in Hospitals2 Cardicac: $491 6.6 6 5.5 951,045 $4,000 MUSD 3 Intensive Care Beds2 122,810 0 2008 2009 2010 2011 2012 2013 2014(1) BCC Research Report Code HLC019D, Published: August 2009 (2) American Hospital Association: Fast Facts on US Hospitals includes, equipment disposal and services. 2009 report.
BPS-Cardiac: Business ModelGoal: License the technology to a major Medical Device Manufacturer – GE Medical Systems – Johnson & Johnson Medical System – BaxterWhere We add value to the Business Model? – Disruptive Technology • Patent • Exclusivity for US/Mexico Markets – Regulatory Compliance • Paperwork • USPTO, FDA, COFEPRIS • Clinical trials – Manufacturing & Testing (1,000 Units)
BPS-Cardiac: The TeamMichele Gonzalez Viridiana Omana Marco Sanchez Fernando Huertaa) Master Science a) Computer Science a) Computer Science a) Alestra Marketing IPN Director: $60M b) Responsible IT b) Manager at usd revenue (’03-b) Mexico City Operation at Guanajuato ’08) Technology Celaya Tech University Council advisor b) 15 years – High c) Responsible IP tech industry.c) Green Travel BPS-Cardiac Agency c) Strategic Alliances: d) Entrepreneur at AOL, Telefonica, Ci Leon Guanajuato. sco.
BPS-Cardiac: Financials (Value Creation)• Product – Target Market US/Mex: – Units Solds: 28,179 – Revenue: $112M usd – Royalties: $13.5 M usd• NPV @12%: Investors, Founders & MDM: $28.6M usd – Investors: 4.0 M usd – Founders: $9.4M usd – Medical Device Manufacturer: 15.2M usd• Payback: – Investors & Founders: 3.9 years – Device Manufacter: 1.2 years
BPS-Cardiac: Funds Required$ 1.56 MUSD VC investment in Medical Devices Startups $719MUSD / Q4 2009Equity: 20%Funds used for:a) Exclusivity (US/Mex)b) FDA/COFEPRIS Approvalsc) USPTO filingd) Clinical Trialse) Manufacturer 1,000 unitsf) Due diligence for contracting MDMExit: Selling IP to a major MedicalDevice Manufacturer.
BPS-Cardiac: Status Licensing contract signed Negotiation: and MDM ready for sale. Medical Dev. Manufacturer (MDM) Raise Funds: $1.56 MUSD Manufacturing 1,000 Units Clinical Trials FDA/COFEPRIS Approvals Lab Scale IP Filing Prototype US/Mex Massive Raising Capital Commercialization $1.56 MUSD R&D Royalties 2005 – 2009 2010 2011 2012 2013
BPS Cardiac: Remember!!!!!!• This is an Excellent Opportunity to invest in a non-invasive low risk disruptive technology that saves people lives.• Business Upsides: More applications can be expanded worldwide and with a potential of developing recurrent business based on disposals.• The opportunity requires an investment of $1.56 MUSD used for key activities to suceed. (IP Lawers and filing and device manufacturing)• And creates an economic value of $28.6M USD.